Advertisement

Prognostic role of copeptin after traumatic brain injury: A systematic review and meta-analysis of observational studies

Published:April 19, 2017DOI:https://doi.org/10.1016/j.ajem.2017.04.038

      Abstract

      Purpose

      Copeptin, the C-terminal portion of provasopressin, has emerged as a novel prognostic marker in neurocritical care, such as in traumatic brain injury (TBI). The aim of this study was to quantitatively assess the prognostic significance of initial plasma copeptin levels in the neurological outcome and mortality after traumatic brain injury.

      Materials and methods

      Six relevant studies with data from 552 patients were included in this meta-analysis.

      Results

      The plasma copeptin levels were found to be significantly higher in patients who died than in the survivors (standardized mean difference [SMD], 1.80). In the four studies reporting Glasgow outcome scale (GOS) data, patients with unfavorable outcomes had significantly higher copeptin levels than those with favorable outcomes (SMD, 1.62). The plasma copeptin level predicted mortality and unfavorable outcomes (AUC, 0.873; AUC, 0.876).

      Conclusions

      The present meta-analysis suggests that early measurement of plasma copeptin levels can provide better prognostic information about the functional outcome and mortality in patients with TBI.

      Keywords

      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hyder A.A.
        • Wunderlich C.A.
        • Puvanachandra P.
        • Gururaj G.
        • Kobusingye O.C.
        The impact of traumatic brain injuries: a global perspective.
        NeuroRehabilitation. 2007; 22: 341-353
        • Roozenbeek B.
        • Maas A.I.R.
        • Menon D.K.
        Changing patterns in the epidemiology of traumatic brain injury.
        Nat Rev Neurol. 2013; 9: 231-236
        • MRC CRASH Trial Collaborators
        Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients.
        BMJ. 2008; 336: 425-429
        • Zitnay G.A.
        • Zitnay K.M.
        • Povlishock J.T.
        • Hall E.D.
        • Marion D.W.
        • Trudel T.
        • et al.
        Traumatic brain injury research priorities: the Conemaugh international brain injury symposium.
        J Neurotrauma. 2008; 25: 1135-1152
        • Kovesdi E.
        • Luckl J.
        • Bukovics P.
        • Farkas O.
        • Pal J.
        • Czeiter E.
        • et al.
        Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics.
        Acta Neurochir. 2010; 152: 1-17
        • Kochanek P.M.
        • Berger R.P.
        • Bayir H.
        • Wagner A.K.
        • Jenkins L.W.
        • Clark R.S.B.
        Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making.
        Curr Opin Crit Care. 2008; 14: 135-141
        • Morgenthaler N.G.
        • Struck J.
        • Alonso C.
        • Bergmann A.
        Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
        Clin Chem. 2006; 52: 112-119
        • Nickel C.H.
        • Bingisser R.
        • Morgenthaler N.G.
        The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department.
        BMC Med. 2012; 10: 7
        • Lipinski M.J.
        • Escárcega R.O.
        • D'Ascenzo F.
        • Magalhães M.A.
        • Baker N.C.
        • Torguson R.
        • et al.
        A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction.
        Am J Cardiol. 2014; 113: 1581-1591
        • Dong X.Q.
        • Huang M.
        • Yang S.B.
        • Yu W.H.
        • Zhang Z.Y.
        Copeptin is associated with mortality in patients with traumatic brain injury.
        J Trauma. 2011; 71: 1194-1198
        • Zhu X.D.
        • Chen J.S.
        • Zhou F.
        • Liu Q.C.
        • Chen G.
        • Zhang J.M.
        Detection of copeptin in peripheral blood of patients with aneurysmal subarachnoid hemorrhage.
        Crit Care. 2011; 15: R288
        • De Marchis G.M.
        • Katan M.
        • Weck A.
        • Fluri F.
        • Foerch C.
        • Findling O.
        • et al.
        Copeptin adds prognostic information after ischemic stroke results from the CoRisk study.
        Neurology. 2013; 80: 1278-1286
        • Zweifel C.
        • Katan M.
        • Schuetz P.
        • Siegemund M.
        • Morgenthaler N.G.
        • Merlo A.
        • et al.
        Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage.
        BMC Neurol. 2010; 10: 34
        • Higgins J.P.
        • Green S.
        Cochrane handbook for systematic reviews of interventions, version 5.1.0.
        The Nordic Cochrane Centre, Copenhagen2011
        • Hayden J.A.
        • van der Windt D.A.
        • Cartwright J.L.
        • Côte P.
        • Bombardier C.
        Assessing bias in studies of prognostic factors.
        Ann Intern Med. 2013; 158: 280-286
        • Choi K.S.
        • Kim H.J.
        • Chun H.J.
        • Kim J.M.
        • Yi H.J.
        • Cheong J.H.
        • et al.
        Prognostic role of copeptin after stroke: a systematic review and meta-analysis of observational studies.
        Sci Rep. 2015; 5: 11665
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Zhou X.H.
        • Obuchowski N.A.
        • DK McClish
        Statistical methods in diagnostic medicine.
        Wiley, New York2002
      1. MedCalc statistical software version 16.8.4.
        MedCalc Software bvba, Ostend, Belgium2016
        • Higgins J.P.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Kleindienst A.
        • Brabant G.
        • Morgenthaler N.G.
        • Dixit K.C.
        • Parsch H.
        • Buchfelder M.
        Following brain trauma, copeptin, a stable peptide derived from the AVP precusor, does not reflect osmoregulation but correlates with injury severity.
        Acta Neurochir Suppl. 2010; 106: 221-224
        • Yu G.F.
        • Huang Q.
        • Dai W.M.
        • Jie Y.Q.
        • Fan X.F.
        • Wu A.
        • et al.
        Prognostic value of copeptin: one-year outcome in patients with traumatic brain injury.
        Peptides. 2012; 33: 164-169
        • Lin C.
        • Wang N.
        • Shen Z.P.
        • Zhao Z.Y.
        Plasma copeptin concentration and outcome after pediatric traumatic brain injury.
        Peptides. 2013; 42: 43-47
        • Cavus U.Y.
        • Yildirim S.
        • Gurer B.
        • Dibek K.
        • Yilmaz D.
        • Ozturk G.
        • et al.
        The prognostic value of plasma Δ-copeptin levels in patients with isolated traumatic brain injury.
        Eur J Trauma Emerg Surg. 2014; 40: 373-378
        • Zhang Z.Y.
        • Zhang L.X.
        • Dong X.Q.
        • Yu W.H.
        • Du Q.
        • Yang D.B.
        • et al.
        Comparison of the performances of copeptin and multiple biomarkers in long-term prognosis of severe traumatic brain injury.
        Peptides. 2014; 60: 13-17
        • Morgenthaler N.G.
        Copeptin: a biomarker of cardiovascular and renal function.
        Congest Heart Fail. 2010; 16: S37-S44
        • Seligman R.
        • Papassotiriou J.
        • Morgenthaler N.G.
        • Meisner M.
        • Teixeira P.J.Z.
        Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia.
        Crit Care. 2008; 12: R11
        • Katan M.
        • Müller B.
        • Christ-Crain M.
        Copeptin: a new and promising diagnostic and prognostic marker.
        Crit Care. 2008; 12: 117
        • Yokobori S.
        • Hosein K.
        • Burks S.
        • Sharma I.
        • Gajavelli S.
        • Bullock R.
        Biomarkers for the clinical differential diagnosis in traumatic brain injury–a systematic review.
        CNS Neurosci Ther. 2013; 19: 556-565
        • Urwyler S.A.
        • Schuetz P.
        • Fluri F.
        • Morgenthaler N.G.
        • Zweifel C.
        • Bergmann A.
        • et al.
        Prognostic value of copeptin: one-year outcome in patients with acute stroke.
        Stroke. 2010; 41: 1564-1567
        • Vakili A.
        • Kataoka H.
        • Plesnila N.
        Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia.
        J Cereb Blood Flow Metab. 2005; 25: 1012-1019
        • Molnar A.H.
        • Varga C.
        • Berko A.
        • Rojik I.
        • Parducz A.
        • Lasclo F.
        • et al.
        Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
        Acta Neurochir. 2008; 150: 265-271
        • Trabold R.
        • Krieg S.
        • Scholler K.
        • Plesnila N.
        Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice.
        J Neurotrauma. 2008; 25: 1459-1465
        • García-Berrocoso T.
        • Giralt D.
        • Bustamante A.
        • Etgen T.
        • Jensen J.K.
        • Sharma J.C.
        • et al.
        B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis.
        Neurology. 2013; 81: 1976-1985